Schaumburg, Illinois, July 9, 2026 – Otsuka Pharmaceutical Factory America, Inc. today announced a planned investment of more than $500 million in Otsuka ICU Medical LLC to expand IV solutions manufacturing capacity in Austin, Texas.
The project will leverage Otsuka Pharmaceutical Factory, Inc.'s long-standing expertise in IV container development and manufacturing quality to support Otsuka ICU Medical LLC's advancement of non-DEHP IV solutions for the North American market.
As part of this initiative, Otsuka ICU Medical LLC will expand its existing 700,000-square-foot Austin manufacturing site and construct a new 500,000-square-foot facility in Austin to support greater operational flexibility and future innovation across IV solutions and specialty pharmaceutical segments.
The expansion represents the first major investment initiative since the formation of Otsuka ICU Medical LLC, the joint venture between ICU Medical, Inc. and Otsuka Pharmaceutical Factory America, Inc., established in 2025. It reflects the partnership's strategic focus on bolstering North American IV solutions manufacturing and innovation, while complementing existing efforts to obtain long-term FDA approval of select overseas Otsuka manufacturing sites to supplement North American supply as needed.
Media Contact:
Peter Kramer, Otsuka Pharmaceutical Factory America, Inc.
512-695-5997
PKramer@opf-america.com
About Otsuka ICU Medical LLC: Otsuka ICU Medical LLC is a joint venture between ICU Medical Inc. and Otsuka Pharmaceutical Factory America, Inc., subsidiary of Otsuka Pharmaceutical Factory, Inc., formed to strengthen the resiliency, reliability, and innovation of IV solutions supply in North America. Combining global manufacturing scale with strong North American production and distribution capabilities, Otsuka ICU Medical LLC supports caregivers with high-quality IV solutions designed to help deliver safe, consistent patient care. For more information, visit www.otsukaicumed.com.
About Otsuka Pharmaceutical Factory, Inc. (OPF): OPF is the original company from which the Otsuka Group has grown. The management vision of OPF is "the best partner in clinical nutrition worldwide", and as a leading company in IV solutions in Japan has been developing, manufacturing, and selling IV solutions for 80 years. Today, in addition to IV solutions, OPF provides a variety of products that contribute to solving issues in the healthcare setting. For more information, visit https://www.otsukakj.jp/en/.
About Otsuka Pharmaceutical Factory America, Inc. (OPFA): OPFA operates across healthcare and life sciences markets engaging in the research, development, technology transfer, manufacture, and sale and importation of pharmaceuticals, IV solutions, medical devices and functional food products. The company also oversees the management and strategic operations of its U.S. subsidiary, Otsuka ICU Medical LLC, and related business activities.
About ICU Medical: ICU Medical Inc. (Nasdaq: ICUI) offers clinically essential medical devices that connect patients and caregivers through life-enhancing, innovative technology, and services that provide meaningful clinical value. The organization's robust portfolio features medical delivery systems and consumable products for infusion therapy, emergency medicine, general and regional anesthesia, home care, NICU/PICU, oncology, pain management, and respiratory care. More information about ICU Medical Inc. can be found at www.icumed.com.